Literature DB >> 18799140

Dendritic cells in vivo: a key target for a new vaccine science.

Ralph M Steinman1.   

Abstract

Dendritic cells (DCs) are the antigen presenting cells that initiate and regulate immunity. By studying these cells in vivo, we will be able to move beyond standard approaches and design vaccines that directly harness the elaborate properties of DCs to control immunity.

Mesh：

Substances：

Year:  2008        PMID： 18799140     DOI： 10.1016/j.immuni.2008.08.001

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  131 in total

1.  Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.

Authors:  Shenghe Tian; Zuqiang Liu; Cara Donahue; Louis D Falo; Zhaoyang You
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.

Authors:  Marcin Kwissa; Helder I Nakaya; Herold Oluoch; Bali Pulendran
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

3.  Age-related Dysregulation of Inflammation and Innate Immunity: Lessons Learned from Rodent Models.

Authors:  Aleah L Brubaker; Jessica L Palmer; Elizabeth J Kovacs
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

Review 4.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

6.  Concomitant activation and antigen uptake via human dectin-1 results in potent antigen-specific CD8+ T cell responses.

Authors:  Ling Ni; Ingrid Gayet; Sandra Zurawski; Dorothee Duluc; Anne-Laure Flamar; Xiao-Hua Li; Amy O'Bar; Sandra Clayton; Anna Karolina Palucka; Gerard Zurawski; Jacques Banchereau; SangKon Oh
Journal:  J Immunol       Date:  2010-08-20       Impact factor: 5.422

7.  Dendritic cells continue to capture and present antigens after maturation in vivo.

Authors:  Scott B Drutman; E Sergio Trombetta
Journal:  J Immunol       Date:  2010-07-19       Impact factor: 5.422

8.  Activation of Antigen-Specific CD8(+) T Cells by Poly-DL-Lactide/Glycolide (PLGA) Nanoparticle-Primed Gr-1(high) Cells.

Authors:  Wen-Hui Luo; Ya-Wun Yang
Journal:  Pharm Res       Date:  2015-12-29       Impact factor: 4.200

9.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

10.  Peptidases released by necrotic cells control CD8+ T cell cross-priming.

Authors:  Jaba Gamrekelashvili; Tamar Kapanadze; Miaojun Han; Josef Wissing; Chi Ma; Lothar Jaensch; Michael P Manns; Todd Armstrong; Elizabeth Jaffee; Ayla O White; Deborah E Citrin; Firouzeh Korangy; Tim F Greten
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.